Evaluating The Utility Of The Modified Cigarette Evaluation Questionnaire And The Cigarette Purchase Task For Predicting Acute Relative Reinforcing Efficacy In Cigarettes Which Vary In Nicotine Content by Bergeria, Cecilia L
University of Vermont
ScholarWorks @ UVM
Graduate College Dissertations and Theses Dissertations and Theses
2018
Evaluating The Utility Of The Modified Cigarette
Evaluation Questionnaire And The Cigarette
Purchase Task For Predicting Acute Relative




Follow this and additional works at: https://scholarworks.uvm.edu/graddis
Part of the Behavioral Disciplines and Activities Commons, and the Psychology Commons
This Dissertation is brought to you for free and open access by the Dissertations and Theses at ScholarWorks @ UVM. It has been accepted for
inclusion in Graduate College Dissertations and Theses by an authorized administrator of ScholarWorks @ UVM. For more information, please contact
donna.omalley@uvm.edu.
Recommended Citation
Bergeria, Cecilia L., "Evaluating The Utility Of The Modified Cigarette Evaluation Questionnaire And The Cigarette Purchase Task For







EVALUATING THE UTILITY OF THE MODIFIED CIGARETTE EVALUATION 
QUESTIONNAIRE AND THE CIGARETTE PURCHASE TASK FOR PREDICTING 
ACUTE RELATIVE REINFORCING EFFICACY IN CIGARETTES WHICH VARY 
IN NICOTINE CONTENT 
 
 



















In Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 






Defense Date:  June 7, 2018 
Dissertation Examination Committee: 
 
Sarah H. Heil, Ph.D., Advisor 
Richard Rawson, Ph.D., Chairperson 
Mark E. Bouton, Ph.D. 
Stephen Higgins, Ph.D. 
Stacey Sigmon, Ph. D. 





Rationale: Nicotine is the addictive component in cigarettes which maintains cigarette smoking 
that subsequently leads to morbidity and mortality.  There are growing regulatory efforts to lower 
the nicotine content in cigarettes so that they are minimally addictive.  Valid methods for 
assessing the abuse liability of cigarettes are essential to these efforts.  While subjective effect 
measures and hypothetical purchase tasks are appealing because they are far easier to administer, 
it is unclear whether these methods can be used to evaluate acute relative reinforcing, a critical 
component of abuse liability.  This secondary analysis sought to evaluate the utility of one 
subjective effects measure, the modified Cigarette Evaluation Questionnaire (mCEQ), and one 
hypothetical purchase task, the Cigarette Purchase Task (CPT), for predicting acute relative 
reinforcing efficacy as measured by concurrent choice Self-Administration (SA) 
Method: Current smokers (N=169) belonging to one of three vulnerable populations 
(socioeconomically disadvantaged women of childbearing age, opioid-maintained individuals, or 
individuals with affective disorders) participated in a multi-site, double blind study evaluating 
research cigarettes with varying levels of nicotine content (0.4, 2.4, 5.2, 15.8 mg/g). In Phase 1 (4 
sessions, 1 research cigarette per session) participants completed the mCEQ and CPT following 
ad-lib smoking of the research cigarette.  In Phase II (6 sessions) cigarette preference was 
assessed using two-dose concurrent choice tests.  Difference scores were calculated for each of 
the five mCEQ subscales and five CPT indices for all six possible dose comparisons evaluated in 
Phase II.  We evaluated the utility of the mCEQ subscale and CPT index difference scores for 
predicting preference for the higher dose in a given dose comparison using a mixed-model of 
repeated measures analysis of variance.  Finally, we used stepwise regressions to determine 
which subscales and indices served as independent predictors of concurrent choice SA. 
Results: Among mCEQ subscales, higher Satisfaction and Enjoyment of Respiratory Tract 
Sensation were independently predictive of higher dose preference in the choice testing regardless 
of dose comparison.  There was a significant Satisfaction X Vulnerable Population interaction 
where increases in Satisfaction difference scores corresponded to greater changes in higher dose 
preference among socioeconomically disadvantaged women of childbearing age compared to 
other Vulnerable Populations.  Among CPT indices, Elasticity was the only independent predictor 
of choice. However, there was a significant Elasticity X Dose Comparison X Vulnerable 
Population interaction associated with its predictive utility where the relationship between 
elasticity and choice differed by dose among opioid-maintained individuals.  In a final model, 
including all subscales and indices, Satisfaction and Enjoyment of Respiratory Tract Sensations 
remained the only significant predictors of choice. 
Discussion:  Concurrent choice testing, subjective effects and hypothetical purchase tasks capture 
some common features of abuse liability.  Concurrent choice testing and the Satisfaction subscale 
were the most concordant measures.  The observation that CPT indices are not robust predictors 
of choice in a concurrent arrangement suggests this measure may have greater utility for 
capturing individual differences as opposed to isolating the acute relative reinforcing effects of 
nicotine.  Nevertheless, all three measures can contribute to efforts to assess the abuse liability of 
cigarettes varying in nicotine dose and important work aimed at regulating these products to 
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CHAPTER 1: INTRODUCTION 
1.1. Public Health Impact of Cigarette Smoking 
Nearly half a million Americans die every year from cigarette smoking-related 
diseases (U.S. Department of Health and Human Services [USDHHS], 2014).  The most 
recent Surgeon General’s report concluded that cigarette smoking causes numerous 
cancers, poor cardiovascular health, adverse reproductive health outcomes, respiratory 
dysfunction as well as diabetes and eye diseases (USDHHS, 2014).  Smoking-related 
health problems cost an estimated $300 billion dollars annually (USDHHS, 2014; Xu, 
Bishop, Kennedy, Simpson & Pechacek, 2015).  Despite the wide array of risks and 
substantial costs, about 15% of Americans are current cigarette smokers (Center for 
Disease Control and Prevention, 2016). 
Cigarettes contain over 5,000 constituents; so far, 93 have been identified as 
harmful or potentially harmful and subsequently categorized as a carcinogen, a 
cardiovascular toxicant, a reproductive or developmental toxicant, a respiratory toxicant 
and/or addictive (Food and Drug Administration [FDA], 2012; Talhout, Schulz, Florek, 
van Benthem, Wester & Opperhuizen, 2011; Royal College of Physicians, 2016).  The 
single constituent that drives persistent use of cigarettes is nicotine (USDHHS, 1988; 
2014).  Indeed, thirty years ago, the Surgeon General’s report concluded that “nicotine is 
the drug in tobacco that causes addiction” (USDHHS, 1988).  Importantly, the dose of 
nicotine obtained from smoking a cigarette influences the addictiveness of the product 
(Benowitz & Henningfield, 1994, Boren, Stitzer & Henningfield, 1990, Donny et al., 
2015, Higgins et al., 2017a, Higgins et al., 2017b, Perkins, Grobe, Caggiula, Wilson & 
Stiller, 1996, Perkins, Kunkle, Michael, Karelitz & Donny, 2016, Shahan et al., 1999).  
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The morbidity and mortality related to cigarette smoking can be conceptualized as a side 
effect of nicotine addiction (Henningfield, 2014).  To address this persistent and harmful 
behavior, public health interventions should target nicotine and its addictive properties.  
In a recent commentary in The New England Journal of Medicine, the current Food and 
Drug Administration Commissioner and the Director of the Center for Tobacco Products 
within the Food and Drug Administration declared their intention to shape a regulatory 
framework to eliminate the use of combustible tobacco products (mainly cigarettes) by 
targeting nicotine (Gottlieb & Zeller, 2017).  Consistent with this report, on March 15th, 
2018, Commissioner Gottlieb issued an advance notice of proposed rulemaking to lower 
nicotine in cigarettes to a minimally or non-addictive level (Tobacco Product Standard 
for Nicotine Level of Combusted Cigarettes, 2018). 
1.2. Reducing Nicotine in Cigarettes 
For decades, research has shown that reducing the amount of nicotine obtained 
from a cigarette reduces its addictiveness (Benowitz & Henningfield, 2013; Boren et 
al., 1990; Donny et al., 2015; Shahan et al., 1999).   The two main approaches to 
reducing the amount of nicotine obtained from smoking have been reducing the 
nicotine yield and reducing the content.  
1.2.1. Reducing Nicotine Yield. Early efforts to reduce the amount of nicotine 
smokers obtained from each cigarette attempted to do so by lowering the nicotine yield of 
a cigarette by altering its physical structure (i.e., increasing the number of holes in the 
filter).  While the tobacco in the cigarette was the same, it was thought that smokers 
would obtain less nicotine because more would escape through the filter holes before 
reaching the smoker.  These modified cigarettes were introduced to the market in the 
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1970s and advertised as “light” cigarettes.   While they are perceived to have lower risks, 
studies indicate levels of exposure are comparable between “light” and “full flavor” 
cigarettes (Benowitz et al., 1983; Benowitz et al., 1986; Yong et al., 2016) as the reduced 
nicotine yield of light cigarettes is easily overcome by a smoker if he/she alters how they 
hold their cigarette (e.g., blocking the filter holes with their lips or fingers). Nicotine 
yield, therefore, does not necessarily correspond to the delivered dose (Kozlowski & 
O’Connor, 2002; Strasser, Ashare, Kozlowski, & Pickworth, 2005).   
1.2.2. Reducing Nicotine Content. Another way to decrease the nicotine dose is 
to lower the nicotine content of a cigarette by manipulating how much nicotine is in that 
cigarette.  Historically, this was done by mixing regular nicotine content tobacco with 
some portion of nicotine-free tobacco (e.g., Boren et al., 1990).  More recently, varying 
nicotine concentrations are achieved by genetically modifying tobacco (e.g., Donny et al., 
2015).  This new method has helped accelerate research testing the long-standing 
hypothesis that there is a so-called nicotine dose threshold for cigarette addiction 
(Benowitz & Henningfield, 1994).   
In their influential New England Journal of Medicine commentary, Benowitz and 
Henningfield (1994) hypothesized that reducing nicotine content to levels less than 0.7 
milligrams of nicotine per gram of tobacco (mg/g) could render cigarettes less addictive 
with the potential to decrease cigarette use and dependence. They based this dose on the 
nicotine intake of cigarette smokers who smoked infrequently and self-reported no 
withdrawal when they abstained from smoking.  Currently, the nicotine content of most 
commercially available cigarettes ranges from 13.5-19.5 mg/g (MacGregor et al., 2014; 
Malson, Sims, Murty & Pickworth, 2001). Cigarettes which fall below commercially 
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available levels of nicotine are referred to as reduced nicotine content (RNC) cigarettes.  
Cigarettes which fall below Benowitz and Henningfield’s threshold are referred to as 
very low nicotine content (VLNC) cigarettes or, in some cases, denicotinized cigarettes.  
Another factor that 
has focused more scientific 
attention on RNC cigarettes 
is the signing of the Family 
Smoking Prevention and 
Tobacco Control Act in 2009 
by President Obama (Figure 
1-1).  This piece of 
legislation gave the FDA the 
ability to reduce, but not 
eliminate, the nicotine in 
cigarettes. Now that nicotine content regulation is within the scope of the FDA’s 
authority, testing Benowitz & Henningfield’s hypothesis is more critical than ever as 
results will influence regulatory policy being formulated right now.   
A growing body of literature indicates that lowering the nicotine content in 
cigarettes renders cigarettes less addictive and decreases cigarette consumption and 
thereby toxicant exposure over extended periods of time (Benowitz et al., 2007; Benowitz 
et al., 2012; Donny et al., 2015; Hatsukami et al., 2010; Hatsukami et al., 2017; Higgins 
et al., 2017a; Higgins et al., 2017b).  In a recent randomized controlled trial published in 
The New England Journal of Medicine, smokers who were not trying to quit and who 
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received VLNC cigarettes free of charge for 6 weeks smoked 30% fewer cigarettes per 
day at the end of the study compared to those who received normal nicotine content 
cigarettes (16 vs. 22 cigarettes per day, respectively; Donny et al., 2015).  Consistently 
with this, smokers assigned to VLNC cigarettes had lower nicotine exposure.  Finally, 
participants who received VLNC cigarettes were more likely to report making a quit 
attempt in the 30 days after completing the study. While this study is the largest and most 
rigorous to date, there are other long-term exposure studies reporting similar outcomes 
(e.g., Benowitz et al., 2007; Hatsukami et al., 2013a; Hatsukami et al., 2017). 
Given increasing interest, methods for assessing the addictiveness of cigarettes 
varying in nicotine content are essential for predicting how these products are used 
among various populations of interest, in contexts when alternative sources of nicotine 
are available or when these products are used in conjunction with other compounds or 
drugs.  Methods for assessing the addictive properties of nicotine-containing products are 
outlined below, with a focus on behavioral measures, specifically self-administration, and 
self-report measures, specifically subjective effect measures and hypothetical purchase 
tasks.  
1.3. Measuring the Addictive Properties of Drugs 
1.3.1. Behavioral Assessments. Addiction is characterized, in part, by high rates 
of drug seeking and use.  In this conceptualization, an objective, behavioral proxy for 
the addictiveness of a drug is its reinforcing properties, or its ability to follow a 
behavior and increase the frequency of that behavior in the future (Schuster & 
Thompson, 1969).  Therefore, reinforcing properties of a drug, in part, predicts the 
abuse liability of a drug. To better understand the addictiveness of a given drug, its 
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reinforcing properties can be studied preclinically and in human laboratory studies 
using SA experiments (Griffiths, Bigelow & Ator, 2003), whereby the delivery of a 
drug is contingent upon a certain operant behavior (e.g., clicking a computer mouse or 
pressing a lever a given number of times to earn puffs on a cigarette).  While 
reinforcing effects measured by SA may not provide a comprehensive analysis of the 
abuse liability of a drug (see review by Johnson & Bickel, 2000), it has been argued 
that the reinforcing effects of a drug may be the most predictive facet of abuse liability 
(see review by Fischman & Foltin, 1991).  Consistent with this, SA outcomes are 
predictive of drug use patterns outside of a laboratory setting (see reviews by Comer, 
Ashworth, Foltin, Johanson, Zacny & Walsh, 2008; Haney & Spealman, 2008).   
To directly observe drug taking behavior within a laboratory session, there are 
often special logistical and time considerations (see review by Panlilio & Goldberg, 
2007).  First, SA experiments typically take place over multiple sessions to allow for 
multiple exposures to the drug. Furthermore, sessions may run for many hours, 
depending on the psychopharmacology of the drug of interest.  Finally, to ensure 
controlled drug delivery, special facilities and equipment are often required (e.g., 
smoking topography devices, rooms with ventilation for smoking). The benefits of 
using such a paradigm, however, is that it allows researchers to isolate the reinforcing 
effects of a drug and to evaluate how numerous factors influence drug taking. 
There are multiple SA arrangements to assess reinforcing value.  Different SA 
arrangements can provide different insights into drugs of abuse and how their 
reinforcing effects may be influenced.  First, drugs can be self-administered at a fixed 
rate (FR) of reinforcement (e.g., drug delivery after every 10 lever presses).  The 
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Response Rate or the amount of drug earned is a proxy for the reinforcing value of the 
drug. Second, progressive ratio (PR) schedules can also be used to assess 
reinforcement.   PR schedules require a subject to emit an operant on a ratio schedule of 
reinforcement that increases every time the drug is earned.  When the demand of the 
schedule is too high, the subject ceases responding.  The highest ratio response 
completed by the subject is referred to as the Breakpoint and is also a measure of the 
reinforcing effects of the drug.  Third, relative reinforcing effects can also be measured 
with concurrent choice SA tasks, where two or more schedules of reinforcement are 
available at the same time.  Concurrent choice SA tasks can include any combination of 
schedules of reinforcement (e.g., FR, PR).  In this paradigm, relative reinforcing value 
can be captured by how often a given reinforcer is chosen in proportion to all choices 
made (Preference).  In all SA paradigms, researchers can isolate factors which 
influence drug taking (e.g., dose, schedule of availability, and availability of other 
reinforcers like money, food and other drugs) to evaluate conditions which influence 
abuse liability.  Broadly speaking, Response Rate, Breakpoint and Preference represent 
a laboratory-derived measure of a drug’s relative reinforcing efficacy which at least 
partially corresponds to the drug’s abuse liability.   
1.3.1.1. Self-administration cigarettes that vary in nicotine content. 
Cigarettes with varying levels of nicotine have been assessed in several SA paradigms. 
When a dose is assessed in isolation, at a fixed rate and in the presence of an alternative 
non-drug reinforcer (i.e., money), SA does not differ across doses (Shahan, Bickel, 
Badger & Giordano, 2001).  Similarly, when tested in isolation under a PR schedule, 
cigarettes with low levels of nicotine show similar Breakpoints to cigarettes with higher 
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doses (Rusted, Mackee, Williams & Willner, 1998; Shahan et al., 1999; Shahan et al., 
2001).  Therefore, when tested separately, it appears that cigarettes with varying dose 
levels do not differ in their reinforcing properties.  However, when two doses are 
concurrently available, numerous studies have shown that subjects show clear 
preference for cigarettes with more nicotine, even under double-blind conditions 
(Boren et al., 1990; Higgins et al., 2017a; Higgins et al., 2017b; Perkins et al., 1996; 
Perkins, Kunkle, Michael, Karelitz & Donny, 2016; Shahan et al., 1999).  Thus, the 
more sensitive behavioral method for the relative abuse liability of cigarettes with 
varying doses is with a concurrent choice paradigm where two cigarettes are 
simultaneously available for self-administration, a finding consistent with early 
research conducted with non-drug reinforcers (Catania, 1963).  However, while SA 
procedures are considered by some to be the gold standard for assessing abuse liability 
(Griffiths, Bigelow & Ator, 2003), they often require substantial time and labor. 
Additionally, SA has been criticized for being an oversimplified method for assessing 
abuse liability.   
1.3.2. Self-Report Measures.  While self-report measures are not direct 
assessments of drug taking behavior, they require considerably less time and labor.  Two 
types of self-report measures, subjective effect measures and the more recently 
developed, hypothetical purchase tasks, have been used to characterize the abuse liability 
of various drugs (Jacobs & Bickel, 1999, see review by Fischman & Foltin, 1991).  
1.3.2.1. Subjective effects.  Subjective effect measures are a long-standing and 
widely used method for assessing different mood states or sensations which may or may 
not accompany the administration of a given drug or dose of a drug.  Generally, early 
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observations found that positive moods or sensations (e.g., euphoria) were more 
frequently documented when assessing drugs which had greater addiction risk (see 
review by Fischman & Foltin, 1991).  Subjective effect measures are easily captured after 
a single exposure to a drug.  
To assess subjective effects of drugs, typically before and immediately following 
exposure to a given drug or dose of a drug, participants indicate whether a given state or 
sensation is present or absent or are asked to assign a score to indicate how severe a given 
state or sensation is on the scale provided (e.g., Likert, visual analog scale).   Items can be 
analyzed individually or can be empirically grouped together to create specific subscales 
(e.g., Aversion subscale made up of individual items of dizziness and nausea).  
Subjective effect scales are often tailored to capture drug-class specific effects (e.g., 
“limp or loose” for sedatives, “shaky or jittery” for stimulants) and can include items to 
evaluate effects associated with routes of administration as well (e.g., assessing throat 
“hit” for a cigarette, Griffiths et al., 2003; Jones, Garret & Griffiths, 1999; Rush, Frey & 
Griffiths; 1999).  Subjective effect measures can capture drug effects and conditioned 
drug sensory effects, all of which contribute to the reinforcing properties of a drug 
(Rupprecht et al., 2015). Furthermore, subjective effects may also distinguish positively 
and negatively reinforcing effects from one another.   
1.3.2.1.1. Subjective effects of cigarettes that vary in nicotine content.  
Subjective effect measures are commonly used in studies assessing cigarettes with 
varying levels of nicotine (Benowitz, Jacob & Herrera, 2006; Boren et al., 1990; 
Butschky, Bailey, Henningfield & Pickworth, 1995; Gross, Lee & Stitzer, 1997; 
Hatsukami et al., 2013a; Higgins et al., 2017a; 2017b; Perkins et al., 1996; 2016; Shahan 
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et al., 1999). While numerous scales have been used to assess subjective effects, there are 
common effects which emerge across measures and reports on cigarettes with varying 
levels of nicotine. Enjoyment, Flavor/Taste, Liking, Satisfaction and Strength are 
common positive subjective effects which increase as a function of the nicotine dose 
delivered by a cigarette (Benowitz et al., 2006; et al., 1990; Butschky et al., 1995; Gross 
et al., 1997; Hatsukami et al., 2013b; Higgins et al., 2017a; 2017b; Perkins et al., 1996; 
2016; Shahan et al., 1999). Common dose-dependent negative subjective effects include 
Aversion, Harshness, Increased Heartbeat, Jitteriness, and Light Headedness/Dizziness 
(Benowitz et al., 2006; Higgins et al., 2017a; Perkins et al., 1996; 2016). While both 
positive and negative subjective effects have been reported, positive effects are more 
frequently documented.   
1.3.2.1.2. Subjective effect measures that predict SA of cigarettes varying in 
nicotine content.  To our knowledge, there are two studies which assess how subjective 
effects correspond to SA and choice of cigarettes which vary in nicotine content.   
One of the two studies which analyzed the relationship between cigarette SA 
preference and subjective effects was very recently published and included a VLNC (0.4 
mg/g) and a normal nicotine content cigarette (15-17 mg/g) (Perkins, Karelitz & Kunkle, 
2018).  This study showed that subjective effect items Liking, Satisfying and How Much 
Flavor, significantly predicted preference for the normal nicotine content cigarette when 
concurrently available with a VLNC.  Subjective effect items How Much Nicotine and 
Strong did not significantly predict choice.   
The second study directly evaluating how well subjective effect data corresponds 
to SA of cigarettes which vary in nicotine content was conducted by our group (Arger et 
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al., 2017).  This study will be described in more detail as it sets the stage for the current 
study.  Arger et al. included 26 participants in a pilot study for a larger laboratory study 
evaluating the acute effects of cigarettes which varied in nicotine content (0.4 mg/g, 2.4 
mg/g, 5.2 mg/g and 15.8 mg/g).  Based on the definitions provided earlier, the 0.4 dose 
cigarette is considered a VLNC cigarette, the two intermediate doses are considered RNC 
cigarettes and the 15.8 cigarette is a normal nicotine content cigarette which 
approximates the dose found in commercially available cigarettes.  Participants came 
from one of three vulnerable populations, namely socioeconomically disadvantaged 
women of childbearing age, opioid-maintained individuals and individuals with affective 
disorders, as smoking is overrepresented among and disproportionately affects these at-
risk groups (Hser, Hoffman, Grella & Anglin, 2001; Lasser, Boyd, Woolhandler, 
Himmelstein, McCormick & Bor, 2000; Schroeder, 2016).   
This study evaluated how well subjective ratings on the modified Cigarette 
Evaluation Questionnaire (mCEQ) measured during initial cigarette sampling sessions 
predicted the relative reinforcing effects of cigarettes evaluated later in the study during 
concurrent choice SA.   The mCEQ consists of 12 questions and is designed to query the 
degree to which a participant experiences the reinforcing effects of smoking.  The 
questionnaire was initially developed and used to evaluate the efficacy of 
pharmacotherapies which were thought to influence the reinforcing effects of cigarette 
smoking (mecamylamine, nicotine replacement, varenicline; Cappelleri et al. 2007; Rose 
et al., 1994; Westman et al., 1992). Research from our group suggests that the mCEQ is 
sensitive to dose differences (Higgins et al., 2017a, 2017b).  However, it does not appear 
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to function differently among individuals with varying levels of nicotine dependence 
(Cappelleri et al., 2007, Higgins et al., 2018).   
The twelve questions of the mCEQ generate five subscales, namely (1) 
Satisfaction, (2) Psychological Reward, (3) Enjoyment of Respiratory Tract Sensations, 
(4) Craving Reduction and (5) Aversion, each made up of 1-5 items (Table 1-1).  
Participants indicated how true a statement was using a Likert scale which ranged from 1 
(Not at all) to 7 (Extremely).  To evaluate different dose comparisons, subjective effect 
difference scores for each of the five subscales were computed by subtracting the lower 
dose cigarette subjective effect score from the higher dose cigarette subjective effect 
score, with positive scores indicating the higher dose cigarette produced greater intensity 
of a subjective effect and negative scores indicating the lower dose cigarette produced 
greater intensity of a subjective effect.  For example, a participant with a Satisfaction 
score of 5 for the 15.8 mg/g dose and 2 for the 0.4 mg/g dose would have a Satisfaction 
difference score of 3.   Difference scores can range from -6 to +6.  Preference for the 
higher dose in the SA task was computed by dividing the number of times the higher dose 
was chosen by the total number of choices made and then multiplied by 100 to derive a 
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percentage. Higher percentages indicated a greater preference for the higher dose.  For 
example, a participant who earned 8 puffs of the 15.8 dose cigarette and 2 puffs of the 0.4 
mg/g dose cigarette while the two doses were concurrently available chose the higher 
dose 80% of the time.  Three dose comparisons (i.e., 15.8 mg/g v. 5.2 mg/g, 15.8 mg/g v. 
2.4 mg/g, 15.8 mg/g v. 0.4 mg/g) were included in the analyses. Dose comparisons not 
including the 15.8 
mg/g cigarette were 
not examined in 






and lower Aversion 
difference scores 
predicted a 
preference for the 
higher dose cigarette when available concurrently with reduced nicotine content 
cigarettes (Figure 1-2).  Psychological Reward, Enjoyment of Respiratory Tract 
Sensations and Craving Reduction effects do not appear to be predictive of concurrent 
choice performance.   
Figure 1-2.  Satisfaction and Aversion subscale difference scores predicting 
preference for the 15.8 mg/g in three dose comparisons.  These two mCEQ 
subscales were equally predictive of choice regardless of dose comparison.  
β represents the fixed effect estimate of the strength of the association 
between the subscale difference scores and % choice for 15.8 mg/g cigarette 
collapsed across dose.  This figure is adapted from “Preliminary validity of 
the modified Cigarette Evaluation Questionnaire in predicting the 
reinforcing effects of cigarettes that vary in nicotine content” by Arger, C. 




Across the two studies that have assessed how behavioral assessments correspond 
to subjective effects of cigarettes which vary in nicotine content, Satisfaction appears to 
be an important subjective effect in predicting SA preference. Negative subjective effects 
(i.e., Aversion) may independently predict preference as well, as documented in one of 
the two studies (Arger et al., 2017).   
While a contribution to the literature, the study conducted by Arger and 
colleagues did not have a large enough sample size to evaluate how well subjective 
effects predict choice in intermediate dose comparisons (e.g., 0.4 mg/g v. 2.4 mg/g). 
Therefore, it is unclear how sensitive the mCEQ is for assessing dose comparisons which 
are closer in magnitude and do not approximate nicotine content found in commercially 
available cigarettes.  In addition, because of the small sample size with small subsets of 
each vulnerable population (socioeconomically disadvantaged women, n = 9; opioid-
maintained patients, n = 11, individuals with affective disorders, n = 6), the preliminary 
analyses could not determine if the mCEQ subscale scores are equally predictive of 
choice across different smoker populations.  
1.3.2.2. Hypothetical purchasing tasks. Purchase tasks are another self-report 
method for assessing the abuse liability of cigarettes that were developed more recently.  
Purchase tasks assess the demand of a given reinforcer across a range of hypothetical 
monetary costs.  This measure incorporates concepts from the field of behavioral 
economics which applies microeconomic theories of demand and supply to understanding 
the maintenance of behavior by their reinforcers.  Purchase tasks can be easily and 
quickly administered after a single exposure to a drug.  
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Typically, hypothetical purchase tasks query the number of units of a given 
commodity (e.g., cigarettes) a participant would want in a 24-hour period at escalating 
price points.  Purchase tasks produce a demand curve which typically shows that 
consumption of a commodity decreases as the price increases.  Using a purchase task, 
drug demand is also characterized by the relationship between total expenditure as a 
function of price per 
drug unit, captured 
with an inverted U-
shaped curve.  From 
these two curves, five 





(1) Intensity (Q0), (2) 
Price per drug unit 
when consumption 
becomes elastic (Pmax), 
(3) Breakpoint (4) 
Maximum Expenditure 
(Omax) and Elasticity 
(α).   Intensity (Q0) 
Figure 1-3. Prototypic demand curve (panel A) and expenditure 
curve (panel B) from which the five indices of the purchase task 
are derived. Adapted from “Bidwell L. C., MacKillop, J., 
Murphy, J. G., Tidey, J. W., Colby, S. M. (2012). Latent factor 
structure of a behavioral economic cigarette demand curve in 




captures drug consumption when there are no costs (i.e., free) and represents 
unconstrained consumption of the reinforcer (Figure 1 – 3, Panel A).  Pmax is the price per 
drug unit when the participant incurs the most costs and represents the point at which the 
demand curve becomes elastic, or sensitive to price (Figure 1 – 3, Panel A and B). 
Breakpoint is the price point at which participants will no longer purchase any cigarettes 
because costs are too high (Figure 1 – 3, Panel A).  Omax is the largest amount of money 
expended in the hypothetical purchase task at a single price point and represents the 
largest cost a participant is willing to incur to obtain a drug (Figure 1 – 3, Panel B).  
Elasticity (α) is an index calculated from the other values that captures the slope of the 
demand curve and describes how consumption is sensitive to escalating prices (not a 
single point on either figure).  While these five indices are often highly correlated, they 
represent unique facets of how the consumption of a reinforcer can be affected by 
monetary constraints.   
1.3.2.2.1. Hypothetical purchase tasks for cigarettes that vary in nicotine 
content.  The Cigarette Purchase Task (CPT) was developed and first tested by Jacobs 
and Bickel (1999) to create a less-burdensome procedure for capturing the reinforcing 
effects of a drug.  Opioid-dependent individuals completed hypothetical purchase tasks 
for cigarettes and heroin and the data from those hypothetical purchase tasks were well 
described by a demand curve typically used to summarize SA data.  Indeed, patterns of 
consumption followed a typical demand pattern where consumption decreased as prices 
increased. While this and other early purchase task studies used hypothetical scenarios, 
subsequent studies have confirmed that the results produced by CPT are highly correlated 
with real and potentially real laboratory cigarette purchasing data (Wilson et al., 2016). 
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Like SA procedures, CPT indices are also sensitive to environmental factors which 
typically influence reinforcers (e.g., deprivation, dose, presence of drug cues; Dahne, 
Murphy & MacPherson, 2016; Higgins et al., 2017b; MacKillop et al., 2012). These 
studies provide converging evidence that acute reinforcing effects are captured with this 
self-report method.  While the CPT was originally designed to be a less burdensome 
complement to SA, its utility appears to extend beyond acute relative reinforcing effects 
as assessed by SA.  Because the CPT takes into consideration the effect of environmental 
constraints on the consumption of cigarettes, it appears to isolate additional factors which 
can influence severity of cigarette use.  This is evidenced by the ability of the CPT to 
detect individual differences like (1) cigarettes smoked per day (Dahne et al., 2016; 
Higgins et al., 2017b; MacKillop et al., 2008; Murphy, MacKillop, Tidey, Brazil & 
Colby, 2011; O’Connor et al., 2014; Secades-Villa, Pericot-Valverde & Weidberg, 2016), 
(2) nicotine dependence scores (Bidwell et al., 2012; Farris et al., 2017; Higgins et al.,  
2018; MacKillop et al., 2008; Murphy et al., 2011; O’Connor et al., 2014; Peters et al., 
2017; Secades Villa et al., 2016; Secades Villa et al., 2017), (3) history of quit attempts 
(Bidwell et al., 2012; Higgins et al., 2017), (4) intensity of craving scores (O’Connor et 
al., 2014; MacKillop, Brown, Stojek, Murphy, Sweet & Niaura, 2012), (4) the presence 
or absence of additional substance use (Farris et al., 2017; Parker et al., 2018) and (5) 
presence or absence of psychopathology (Dahne et al., 2016; Farris et al., 2017; 
MacKillop & Tidey, 2011; Secades Villa et al., 2016, 2017).  These results suggest that 
the CPT is a relevant tool for assessing abuse liability and clinically meaningful 
individual differences related to abuse liability. 
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 Likely because it was developed more recently, the CPT has been used 
infrequently to characterize the abuse liability of cigarettes with varying nicotine content.  
For example, in the large randomized trial by Donny and colleagues (2015) that evaluated 
cigarettes with varying levels of nicotine and was described earlier, participants who 
were assigned to smoke the lowest dose cigarette (0.4 mg/g) reported that after 6 weeks 
of use, their assigned cigarette had significantly lower Intensity (Q0), Maximum 
Expenditure (Omax) and Breakpoint and higher Elasticity (α) compared to cigarettes with 
higher doses of nicotine (Smith et al., 2016).  In addition, the recent laboratory study by 
our group assessing cigarettes with varying levels of nicotine among vulnerable 
populations also captured differences in cigarette purchase task indices after a single 
exposure to the cigarettes.  Specifically, very low nicotine content cigarettes had 
significantly lower Intensity (Q0), Price at point of Elasticity (Pmax), Breakpoint and 
Maximum Expenditure (Omax) compared to cigarettes with higher doses of nicotine 
(Higgins et al., 2017).   
1.3.2.2.2. Purchase task indices which predict SA. While the existent literature 
on the CPT consistently captures a range of individual differences, there is only one study 
which directly tested the relationship between purchase tasks and SA data.  In a study 
involving normal nicotine content cigarettes and other tobacco products, Breakpoint for 
cigarettes derived from SA under a progressive ratio schedule of reinforcement did not 
consistently correspond with the number of cigarettes subsequently purchased in a 
laboratory purchasing task (Stein et al., 2017).  Specifically, Breakpoint derived from SA 
under a progressive ratio schedule of reinforcement positively and significantly 
corresponded to laboratory purchases of cigarettes at the lowest price (12¢ each), but not 
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at higher prices (25¢, 50¢ or $1 each).  These results were somewhat surprising but could 
possibly be an artifact of the study design, which assessed cigarettes and other tobacco 
products in isolation with SA but pairs of tobacco products in the laboratory purchasing 
tasks.  Further, this study was limited because of its inability to describe the relationship 
between specific indices of the CPT and SA because in many cases the indices were 
inestimable with participant-level data.  
The CPT may offer unique information about the abuse liability of cigarettes and 
could inform regulatory efforts to address the addictiveness of cigarette smoking (Tidey 
et al., 2016).   The single study where the relationship between CPT and SA was assessed 
was limited to normal nicotine content cigarettes and involved general population 
smokers.  It remains to be seen how indices derived from the CPT correspond to data 
collected from SA paradigms. 
1.4 Aims 
Our research group recently completed the laboratory-based study which was 
piloted in the sample evaluated by Arger and colleagues (Higgins et al., 2017b).  The 
completed study included data from 169 individuals who completed all phases of the 
study.  This sample size allowed us to extend the work of Arger et al. (2017) by assessing 
all six dose comparisons and determining the generalizability of the predictive validity of 
the mCEQ in various smoker populations.  In addition, the CPT was collected which 
allowed us to exam the correspondence of CPT indices with choice preference assessed 
in a concurrent choice SA paradigm.   
Based on previous research with the mCEQ, it was hypothesized that Satisfaction 
and Aversion would predict choice.  Because previous studies on the topic were limited 
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by sample size or did not include vulnerable populations, no specific hypotheses were 
made regarding predictive utility as a function of dose comparison or vulnerable 
population. 
 With regards to the CPT, it was unclear what index or indices might best 
correspond to preference given the relative dearth of studies on the topic.  Theoretically, 
one might hypothesize that relative Intensity (Q0) for two cigarettes (i.e., the difference in 
the number of cigarettes of each dose a smoker would smoke if both cigarettes were free) 
would be most likely to correspond to preference for cigarettes available under an equal 
response cost.  As there are no data to our knowledge to suggest that the relationship 
between Intensity and choice would vary across dose comparison nor vulnerable 
population, no specific hypotheses were made regarding potential interactions of 






CHAPTER 2: METHOD 
The parent study for this secondary analysis is a large, multisite, 14-visit 
laboratory-based study evaluating the acute effects of cigarettes with varying levels of 
nicotine under double blind conditions among three vulnerable populations 
(socioeconomically disadvantaged women of childbearing age, opioid-maintained 
individuals and individuals with affective disorders, Higgins et al., 2017b).  Data were 
collected using the same protocol utilized by Arger and colleagues (2017) that was 
briefly described in the Introduction.  Procedures relevant to the present analyses are 
described in more detail below. 
2.1. Participants 
We used data collected from 169 smokers (53 socioeconomically disadvantaged 
women, 60 opioid-maintained men and women and 56 men and women with affective 
disorders) who completed all 14 sessions of the study.  Participants were recruited via ads 
on Facebook, Craigslist, and in local newspapers, as well as flyers posted on community 
bulletin boards.  The study took place at three sites: the University of Vermont in 
Burlington, VT: Johns Hopkins University in Baltimore, MD; and Brown University in 
Providence, RI.  All potential participants attended a two-hour screening session.  After 
providing informed consent, potential participants submitted breath samples (Micro+ 
Smokerlyzer; coVita/Bedfont, Haddonfield, NJ) and urine samples (NicAlert cotinine test 
strip; Nymox, Hasbrouck Heights, NJ) to determine smoking status; urine samples were 
also tested for pregnancy status.  Next, potential participants completed demographic 
(e.g., age, race/ethnicity, education, marital status, etc.) and medical history 
questionnaires developed in our laboratory, and then completed a series of standardized 
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questionnaires about their tobacco use, including the Fagerstrom Test for Nicotine 
Dependence, (FTND, Heatherton, Kozlowski, Frecker & Fagerstrom  1991; Pomerleau, 
Majchrzak, & Pomerleau, 1989; Pomerleau, Carlton, Lutzke, Flessland & Pomerleau, 
1994), and their mental health history, including the Mini International Neuropsychiatric 
Interview (MINI) 6.0 (Sheehan et al., 1998) and the Beck Depression Inventory (Beck, 
Ward & Mendelson, 1961).   
To be eligible, participants self-reported using at least 5 cigarettes per day for the 
past year and had an intake breath carbon monoxide (CO) sample > 8 ppm.  Individuals 
were excluded if they reported exclusively rolling their own cigarettes, using other 
tobacco or nicotine products 9 or more days in the last 30 days, or any smoking cessation 
product use in the last 30 days.  All participants were without current serious mental 
disorders, lifetime psychosis or dementia, substance abuse, and suicidal ideation.  In 
addition to the above-mentioned inclusion criteria, the three vulnerable populations of 
interest had additional population-specific inclusion criteria.  Socioeconomically 
disadvantaged women were between the ages of 18 and 44 and their highest level of 
educational achievement was a high school degree.  Opioid-maintained individuals were 
between the ages of 18 and 70 and their prescribing physician confirmed they had >70% 
drug-free urines in the past month.  Finally, participants with affective disorders were 
between the ages of 18 and 70 and met criteria on the MINI for major depression 
disorder, general anxiety disorder, post-traumatic stress disorder, obsessive compulsive 






2.2.1. Research cigarettes. Spectrum nonmenthol and menthol research 
cigarettes were manufactured by 22nd Century (Clarence, NY) in conjunction with the 
National Institute of Drug Abuse.  The doses used in the current protocol were 0.4, 2.4, 5.2 
and 15.8 mg/g. 
2.2.2. CReSS desktop smoking topography device 
To implement controlled 
puffing procedures that would be 
used in later phases of the study, 
participants smoked all research 
cigarettes through the CReSS 
Desktop Smoking Topography 
Device (Borgwaldt, Richmond, 
Virginia).  The smoking topography 
device is an 8” X 6” X 5” console 
with two tubes connected to the 
front (Figure 2-1, Panel A).  The 
tubes extend about three feet and 
connect to a mouthpiece which 
holds a cigarette (Figure 2-1, Panel 
B).  Individuals smoke the cigarette through the mouthpiece.  The device can measure 
several parameters of puffing behavior including length, size and velocity.  All data are 
24 
 
transferred from the console to a desktop PC via a USB cable.  Puff volume is displayed 
on a computer screen in real time.  Researchers can also display target puff volumes and 
timers to guide participants to puff in specific patterns.  The CReSS Smoking 
Topography Device has been shown to have good reliability and validity (Blank, 
Disharoon & Eissenberg, 2008; Lee, Malson, Waters, Moolchan, & Pickworth, 2003).   
2.2.3. Modified Cigarette Evaluation Questionnaire (mCEQ).  As described 
previously, the mCEQ captures subjective effects of cigarette smoking.  Participants rate 
each of the 12 questions (Table 1-1) on a Likert scale which ranges from 1 (not at all) to 7 
(extremely).  The answers are combined to form five unique subscales which quantify (1) 
Satisfaction, (2) Psychological Reward, (3) Enjoyment of Respiratory Tract Sensations, (4) 
Craving and (5) Aversion.  The mCEQ was originally designed to measure changes in the 
reinforcing effects of smoking following a pharmacological intervention (Brauer et al., 
2001, Rose et al., 1994, Rose et al., 1998, Westman et al., 1992).  The most recent version 
was developed and validated according to data collected from three clinical trials testing 
the effects of varenicline for smoking cessation (total N = 1,565; Cappelleri et al., 2007).  
The subscales which make up the questionnaire used in this study demonstrate satisfactory 
convergent validity and have demonstrated good test-retest reliability. 
2.2.4. Cigarette Purchase Task (CPT).  As described in the introduction, the 
CPT queries how many cigarettes a participant would purchase at various given prices.  
The instructions when participants completed the CPT are as follows:  
Think about HOW YOU ARE FEELING RIGHT NOW.  The following   
questions how many cigarettes you would smoke if they cost various amounts of 
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money.  ASSUME THAT: (1) The available cigarettes are your assigned study 
cigarettes. (2) You have the same income/savings that you have now and NO 
ACCESS to any cigarettes or nicotine products other than those offered at these 
prices. (3) You can smoke without any restrictions and without factoring in what 
might occur in the next 24 hours related to your participation in the study. (4) You 
would smoke the cigarettes that you request at this time, not save or stockpile 
cigarettes for a later date. Be sure to consider each price increment carefully. 
Participants then provided responses for how many cigarettes they would 
purchase at 20 different price points per cigarette (free, 2¢, 5¢, 10¢, 20¢, 30¢, 40¢, 50¢, 
60¢, 70¢, 80¢, 90¢, $1, $2, $3, $4, $5, $10, $20, $40).  Each price point was shown as 
price per cigarette and price per pack (e.g., $1 per cigarette OR $20 per pack).  After 
completing the CPT, research assistants reviewed the data to assess any unsystematic 
data (e.g., increasing consumption across increasing prices, decreases in consumption as 
price points increased followed by increases in consumption at higher price points).  If 
the data followed unsystematic patterns, research assistants re-explained the task and 
gave the participant an opportunity to change their data. 
2.2.4.1. Computing CPT indices.  Four of the five indices of the CPT (Intensity 
(Q0), Pmax, Breakpoint, Omax,) were empirically quantified from observed values. As 
discussed in the Introduction, Intensity is the quantity of cigarettes ‘purchased’ when they 
were free, Omax is the largest sum incurred in a single price condition when hypothetically 
purchasing cigarettes, Pmax is the price point at which Omax occurs and represents the 
point at which participants become sensitive to price and Breakpoint is the point at which 
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a participant first reports they would purchase zero cigarettes, presumably because the 
costs are too high. 




C) – 1)) where Q is the quantity consumed, Q0 is the quantity consumed when 
the cigarette is free (y-intercept), k is the range of the cigarettes consumed in logarithmic 
units and was kept constant across all individual curve fits and C equals the unit price.  
To log transform the data and model the demand curve, price points where participants 
reported smoking zero cigarettes were replaced with .001.  α represents individual 
differences in the rate of change in consumption with changes in price (i.e., Elasticity; 
Hursh & Silberberg, 2008) and was derived for each participant from the demand curve 
based upon their responses.   
2.3 Procedures 
If deemed eligible at the screening visit, participants were invited to participate in 
the study.  Participants completed each of the 14 visits under acute abstinence which was 
biochemically verified with at least a 50% reduction in their screening CO value; this is 
an abstinence criterion widely used in tobacco research (e.g., Johnson, Bickel & 
Kirshenbaum, 2004; Tidey, O’Neill & Higgins, 1999).  The study was divided into a 
baseline visit and three phases (Phases 1 – Phase 3).  All laboratory sessions took place in 
a small room (30 ft2) with a ventilation system specifically designed to allow for cigarette 
smoking indoors.  The rooms had two computers, a laptop and a desktop computer, 
which were used to (1) complete questionnaires and complete the concurrent choice 
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program and (2) measure smoking behavior, respectively.  The analyses proposed will 
use data from Phases 1 and 2, which are described in more detail below.  
Phase 1 consisted of four visits where participants sampled a single research 
cigarette on distinct days and provided subjective effect ratings and CPT responses.  
After biochemical confirmation of acute abstinence, participants took 2 ad lib puffs on 
their usual brand cigarette.  This was done to equate the time since last puff across all 
participants.  After a 30-minute period, participants smoked the assigned research 
cigarette ad lib through the desktop smoking topography device.  Each cigarette was 
labelled with an arbitrary letter code (e.g., A, B, C and D) which differed depending on 
the sequence to which each participant was randomized.  While smoking the cigarette, 
participants were encouraged to take detailed notes on their smoking experience, which 
were saved for Phase 2.  Immediately after smoking the cigarette, participants completed 
the mCEQ and CPT.  In the hour that followed, participants completed other 
questionnaires and provided CO samples at fifteen-minute intervals; those data have been 
reported elsewhere (Higgins et al., 2017b).  At the end of the hour, participants practiced 
controlled puffing procedures with specific puffing size and length requirements with the 
same dose research cigarette.  
 Phase 2 consisted of six visits where participants chose between two cigarettes, 
both available on a fixed-ratio schedule of 
reinforcement (FR-10).  Each dose comparison was 
tested once in separate sessions (Table 2-1).  
Participants were randomized to a dose comparison 
presentation sequence.  As in Phase 1, researchers 
Table 2-1. Nicotine Dose Comparisons  
 
15.8 mg/g 0.4 mg/g 
15.8 mg/g 2.4 mg/g 
15.8 mg/g 5.2 mg/g 
5.2 mg/g 0.4 mg/g 
5.2 mg/g 2.4 mg/g 
2.4 mg/g 0.4 mg/g 
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biochemically confirmed acute abstinence at the beginning of each Phase 2 session and 
participants took two puffs on their usual brand cigarette and waited 30 minutes before 
beginning session procedures.  Two different dose cigarettes labelled with the letter codes 
used in Phase 1 were available to smoke.  Researchers provided participants with a copy 
of their notes from Phase 1.  When participants wanted to smoke a certain cigarette, they 
clicked 10 times on an icon on the laptop computer which had the letter code of the 
corresponding cigarette (Figure 2-2).   Participants then lit the selected cigarette without 
inhaling, placed it in the mouth piece of the desktop smoking topography device and took 
two controlled puffs exactly as they practiced in Phase 1 and with feedback displayed on 
the desktop monitor. 
Participants were 
given 2 minutes to 
take the two puffs.  
During each 3-hour 
session in Phase 2, 
participants could 
make as many or as 
few choices for 
either cigarette as 
they wanted.   
2.4 Statistics 
All statistical data preparation and analyses were conducted using Statistical 
Analysis Software (SAS) version 9.4.  Significance testing was determined at p < .05. 
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2.4.1. Preparing Data for Analysis.   
2.4.1.1. Predictor variables. As previously described, difference scores were 
calculated for each mCEQ subscale by subtracting scores for the lower dose from scores 
of the higher dose for each of the six dose comparisons.  Difference scores can range 
from - 6 to + 6 and more positive difference scores indicated greater subjective effects at 
the higher dose.   
For CPT data, Elasticity values greater than 1.00 were winsorized to 1.00 prior to 
statistical analysis (22 of 845 cases).  All other demand indices were empirically 
quantified from observed values.  We reviewed CPT results and found systematic 
patterns in 92.7% of demand curves; no data were excluded from analyses.  In cases 
where participants reported zero consumption across all prices (54 of 845 cases), curve 
fitting was not possible, so Elasticity was not analyzed, and other demand indices were 
quantified as 0.  Demand curves for the four doses of cigarettes had R2s which ranged 
from 0.97 - 0.98, indicating that the demand curves sufficiently described the pattern of 
the data collected. 
Once all indices were empirically quantified, difference scores were calculated for 
each of the five CPT indices using the same approach used for each mCEQ subscale.  
Ranges depended on the index being computed.  
2.4.1.2. Outcome variables. To quantify relative reinforcing effects of the cigarettes 
using data from the concurrent choice assessment, a ratio was calculated for each of the 
six dose comparisons.  Each ratio was computed by dividing the total puffs earned for the 
higher of the two doses available by the total puffs earned in the choice session.  Ratios 
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were multiplied by 100 to produce a percentage, with higher percentages indicating more 
choices for the higher dose cigarette.   
𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑓𝑓𝑠 𝐸𝑎𝑟𝑛𝑒𝑑 𝑓𝑜𝑟 𝐻𝑖𝑔ℎ𝑒𝑟 𝐷𝑜𝑠𝑒
𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑓𝑓𝑠 𝐸𝑎𝑟𝑛𝑒𝑑
    X      100 
2.4.2. Assessing the Predictive Utility of Individual Subscales and Indices. The 
aims of the statistical analyses were to assess how well mCEQ subjective effect 
difference scores and CPT index differences scores predict preference for the higher dose 
in a given dose pair.  Mixed effects repeated measures analysis of variance tests were 
used to predict proportion of choices for the higher dose with dose comparison as the 
repeated fixed effect and mCEQ and CPT difference scores, the main independent 
variables of interest, as a fixed effect.  This allowed us to evaluate whether subjective 
effects and CPT indices were predictive of choice at all dose comparisons.   
There were five variables which were included in the statistical analyses for the 
primary aim to account for any variability introduced by the design of the parent study.  
They remained in the model regardless of whether they were predictive of choice.  The 
model included a fixed effect for session and a random effect for the sequence of dose 
comparison presentations since participants were randomized to receive all dose 
comparisons within a Latin square design.  Vulnerable population group was entered as 
an additional fixed effect as the study included three vulnerable population groups which 
varied in how they were recruited and their inclusion criteria.  Site (i.e., University of 
Vermont, Johns Hopkins University and Brown University) was also included in the 
model as a random effect.  Finally, because participants could take as many or as few 
puffs as that they wanted in the choice session, total puffs earned were entered as an 
31 
 
additional fixed effect in all models testing the predictive utility of the mCEQ and CPT 
for predicting choice.  
Interaction terms were included in the model to evaluate how well mCEQ or CPT 
difference scores predicted choice and whether this depends on dose comparison or 
vulnerable population group.  If any interaction terms were not significantly predictive of 
choice, the term was eliminated, and the model was re-run without the nonsignificant 
interaction term.  This process was repeated until the model contained only main effects 
or main effects and significant interaction terms.  
2.4.3. Assessing Independent Predictors of Choice. After each subscale was 
evaluated independently, two separate models evaluated which mCEQ subscales were 
independent predictors of choice and which CPT indices were independent predictors of 
choice.  This first model included all of the subscale difference scores as a fixed effect.  
Non-significant subscales with the highest p-value were removed from the model and the 
model was rerun until the only subscales which remained were significant predictors of 
choice.  This process was repeated for a second model evaluating which CPT indices 
were significant, independent predictors of choice.  
In a final model, all five mCEQ subscales and all five CPT indices were entered as 
predictors of choice.  Again, predictors with the largest p-values were removed from the 
model and the model was rerun until only significant subscales or indices remained in the 
model.   
2.4.4. Power Analysis.  Using data from the pilot study (Higgins et al., 2017a), 
similar analyses using a sample of 26 individuals resulted in a statistically significant 
effect of differences in Satisfaction and Aversion on the choice of cigarettes with an eta-
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squared of 0.08 and 0.05, respectively (Arger et al., 2017).  Our sample size of 169 is 





CHAPTER 3: RESULTS 
3.1. Participant Characteristics 
 As 
reported in 
Higgins et al. 
(2017b), the 
majority of the 
169 participants 
were female, 
Caucasian, had a 
high school 
education or less 
and were never 
married (Table 3-
1).  
 On average, participants smoked 16 cigarettes per day and 35% of participants 
were primary menthol cigarette smokers. Participants started smoking regularly at 16 
years old and had moderate levels of dependence according to the Fagerstrӧm Test for 
Nicotine Dependence. These factors did not significantly differ by group, therefore we 





Table 3-1. Participant Characteristics     
  











Age (mean yrs + SD) 
35.6 ± 
11.4 
30.0 ± 7.0 41.0 ± 11.2 35.0 ± 12.4 
Gender (% Female) 71 100 60 55 
Race (%)     
       White 73 77 70 71 
       American Indian/Alaskan Native 0 0 0 0 
       Asian 0.6 0 0 2 
       Black/African-American 14 15 20 5 
       Native Hawaiian/Pacific Islander 0.6 0 2 0 
       Other/more than 1 race 9 4 9 14 
       Latino 3 4 0 6 
Education (%)     
  8th Grade or Less 2 2 3 2 
  Some High School 14 17 17 7 
  High School Graduate/Equivalent 34 38 37 28 
  Some college 38 43 35 36 
  2-Year Associate’s Degree 6 0 8 9 
  College Graduate/4-Year Degree 3 0 0 11 
  Graduate or Professional Degree 2 0 0 7 
Marital Status (%)     
       Married 15 27 7 14 
       Never Married 61 64 53 66 
       Divorced/Separated 21 8 35 17 
       Widowed 2 2 3 2 
Cigarettes per Day (M + SD) 15.8 ± 7.5 14.5 ± 6.3 16.5 ± 6.1 16.3 ± 9.5 
Primary Menthol Smoker (%) 35 30 38 36 
Age Started Smoking Regularly (mean yrs + SD) 16.3 ± 4.3 16.4 ± 3.7 16.2 ± 5.5 16.2 ± 3.1 
Fagerstrm Test for Nicotine Dependence (M + SD) 5.0 ± 2.2 4.6 ± 2.3 5.3 ± 1.8 5.0 ± 2.3 
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3.2. Descriptive Statistics for Predictor and Outcome Variables 
mCEQ subscale and CPT index difference score means and standard errors are 
presented for each dose comparison in Tables 3-2 and 3-3.  As reported in Higgins et al. 
(2017b), participants showed dose-dependent increases in all five mCEQ subscales and 
four of the five CPT indices (Intensity, Pmax, Breakpoint, Omax).  Means and standard 
errors for the proportion of choices for the higher dose cigarette in the six dose pairs are 
summarized in Table 3-4.  As reported in Higgins et al. (2017b), participants showed 
significantly greater preference for the higher dose in a given dose pair with greater 
preference shown when the dose contrast was larger.  
Table 3-2. Mean (SE) mCEQ Subscale Difference Scores by Dose Comparison 
 Dose Comparison 
Subscale 0.4 vs. 2.4 2.4 vs. 5.2 0.4 vs. 5.2 5.2 vs. 15.8 2.4 vs. 15.8 0.4 vs. 15.8 
Satisfaction 0.41 (0.14) 0.26 (0.13) 0.67 (0.13) 0.77 (0.14) 1.03 (0.14) 1.45 (0.14) 
Psychological 
Reward 





0.22 (0.14) 0.42 (0.13) 0.64 (0.14) 0.58 (0.14) 1.00 (0.16) 1.22 (0.16) 
Craving 
Reduction 
0.30 (0.16) 0.29 (0.15) 0.59 (0.15) 0.57 (0.15) 0.96 (0.15) 1.15 (0.17) 
Aversion 0.04 (0.05) 0.01 (0.06) 0.04 (0.06) 0.24 (0.07) 0.24 (0.08) 0.28 (0.07) 
Table 3-4. Mean (SE) Proportion of Choice for Higher Dose in a Give Dose Pair 
 Dose Comparison 





.58 (.03) .57 (.03) .62 (.03) .64 (.03) .68 (.03) .71 (.03) 
 
Table 3-3. Mean (SE) CPT Index Difference Scores by Dose Comparison 
 Dose Comparison 
CPT 
Index 
0.4 vs. 2.4 2.4 vs. 5.2 0.4 vs. 5.2 5.2 vs. 15.8 2.4 vs. 15.8 0.4 vs. 15.8 
Elasticity -0.06 (0.02) -.02 (0.01) -0.21 (0.01) -0.02 (0.01) -0.04 (0.02) -0.04 (0.02) 
Intensity 0.40 (0.82) 1.59 (0.61) 2.03 (0.69) 0.44 (0.66) 2.05 (0.76) 2.52 (0.88) 
Omax -4.61 (6.41) 3.93 (4.30) -0.44 (3.49) 8.79 (4.71) 12.53 (7.83) 8.51 (4.74) 
Pmax 0.10 (0.57) 0.42 (0.52) 0.52 (0.63) 0.72 (0.68) 1.14 (0.67) 1.25 (0.58) 
Breakpoint 0.36 (0.92) 0.55 (0.98) 0.91 (0.93) 1.07 (1.00) 1.63 (0.75) 2.32 (0.87) 
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3.3. mCEQ Subscales as Predictors of Choice 
 When analyzed separately, all five mCEQ subscales were predictive of choice.   
3.3.1. Satisfaction.  Satisfaction was significantly predictive of choice regardless 
of dose comparison, β = .07, F(1, 999) = 211.16, p < .0001 (Figure 3-1, Panel A).  
Specifically, greater differences in Satisfaction scores were associated with greater 
preference for the higher dose cigarettes; for every 1-point increase in Satisfaction 
subscale scores, preference for the higher dose cigarette increased by 7%.    
 The final model used to evaluate the predictive utility of Satisfaction for cigarette 
preference included one interaction term which was statistically significant (Satisfaction 
X Vulnerable Population), F(2, 998) = 10.06, p < .001 (Figure 3-2).  Across all 
Figure 3-1. mCEQ subscale difference scores and cigarette preference across six dose comparisons 
(gray lines) and collapsed across dose comparisons (black lines). mCEQ subscales did not predict 
choice differently across the dose comparisons (Subscale X Dose Comparison, p’s > .05). 
B A 
E D C 
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populations, greater Satisfaction 
difference scores corresponded to 
greater preference for the higher dose 
cigarette.  However, socioeconomically 
disadvantaged women appeared to show 
greater increases in behavioral 
preference as Satisfaction difference 
scores increased.  Specifically, 
socioeconomically disadvantaged 
women showed an 11% increase in 
higher dose cigarette preference for every 1-point increase in Satisfaction difference 
scores while individuals who were opioid-maintained and individuals with affective 
disorders showed a 6% increase in higher dose cigarette preference for every 1-point 
increase in Satisfaction. Post-hoc analyses controlling for sex, age and education did not 
eliminate the significant interaction between satisfaction and vulnerable population for 
predicting choice whereby changes in Satisfaction subscale difference scores 
corresponded with larger increases in preference for the higher dose cigarette.  Sex, age 
and education were considered in post-hoc analyses because participants were 
specifically recruited/enrolled based on these factors.   
3.3.2. Psychological Reward. Psychological Reward was predictive of choice 
regardless of dose comparison and vulnerable population, β = .07, F(1, 1003) =  95.01, p 
< .0001 (Figure 3-1, Panel B).  Specifically, greater differences in Psychological Reward 
scores were associated with greater preference for the higher dose cigarettes; for every 1 
Figure 3-2. Satisfaction difference scores and 
cigarette preference, collapsed across dose 
comparisons and separated by project. 
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point increase in Psychological Reward, preference for the higher dose cigarette 
increased by 7%.  The final model used to evaluate the predictive utility of Psychological 
Reward for cigarette preference did include any interaction terms.   
3.3.3. Enjoyment of Respiratory Tract Sensations.  Enjoyment of Respiratory 
Tract Sensations was predictive of choice regardless of dose comparison and vulnerable 
population, β = .06, F(1, 1004) = 141.17, p < .0001 (Figure 3-1, Panel C).  Specifically, 
greater differences in Enjoyment of Respiratory Tract Sensations were associated with 
greater preference for the higher dose cigarettes; for every 1-point increase in Enjoyment 
of Respiratory Tract Sensations, preference for the higher dose cigarette increased by 5%.  
The final model used to evaluate the predictive utility of Enjoyment of Respiratory Tract 
Sensations for cigarette preference did not include any interaction terms.   
3.3.4. Craving Reduction.  Craving Reduction was predictive of choice 
regardless of dose comparison and vulnerable population, β = .03, F(1, 1002) = 45.35, p 
< .0001 (Figure 3-1, Panel D).  Specifically, greater differences in Craving Reduction 
were associated with greater preference for the higher dose cigarettes; for every 1 point 
increase in Craving Reduction, preference for the higher dose cigarette increased by 6%.  
The final model used to evaluate the predictive utility of Craving Reduction for cigarette 
preference did not include any interaction terms.  
3.3.5. Aversion.  Aversion was predictive of choice regardless of dose 
comparison and vulnerable population, β = .03, F(1, 1003) = 4.66, p = .03 (Figure 3-1, 
Panel E).  Specifically, greater differences in Aversion were associated with greater 
preference for the higher dose cigarettes; for every 1-point increase in Aversion, 
preference for the higher dose cigarette increased by 3%.  The final model used to 
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evaluate the predictive utility of Aversion for cigarette preference did not include any 
interaction terms.   
Because Aversion predicted choice in the opposite direction of previous findings 
by Arger et al. (2017), post-hoc analyses examined how the two items comprising the 
Aversion subscale (Nausea and Dizziness) predicted choice.  Both Nausea and Dizziness 
scores were significantly predictive of choice across dose comparisons and vulnerable 
population. However, Nausea was significantly negatively predictive of choice, β = -.02, 
F(1, 1003) = 4.23, p =.04, and Dizziness scores were significantly positively predictive of 
choice, β = .04, F(1, 1003) = 22.61, p <.001. 
3.3.6. mCEQ Subscales as Independent Predictors. When all five subscales 
were included in a final model to test which subscales were independent predictors of 
cigarette preference, only Satisfaction and Enjoyment of Respiratory Tract Sensations 
remained significant, β = .06, F(1, 1001) = 52.32, p < .0001, β = .02, F(1, 1001) = 7.03, p 
< .01, respectively.  Higher Satisfaction and higher Enjoyment of Respiratory Tract 
Sensations scores for the high dose cigarette corresponded to a higher proportion of 
choices for the high dose cigarette. Specifically, for every 1-point increase in Satisfaction 
or Enjoyment of Respiratory Tract Sensation difference scores, participants selected the 
higher dose cigarette 6% and 2% more, respectively. 
3.4. CPT Indices as Predictors of Choice  
 When analyzed separately, Intensity and Elasticity were predictive of choice and 
Omax, Pmax and Breakpoint were not.  
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3.4.2. Intensity.  Intensity was significantly and positively predictive of choice, β 
= -.002, F(1, 944) = 19.44, p < .001.  Specifically, higher Intensity corresponded to a 
greater preference for the higher dose cigarette.   
The final model used to assess the predictive utility of Intensity included a 
significant Intensity X Dose Comparison X Vulnerable Population interaction.  This 
interaction revealed that Intensity is predictive in socioeconomically disadvantaged 
women of childbearing 
age (β = .02, F(1, 288) 
= 18.35, p < .001) and 
individuals with 
affective disorders (β = 
.004, F(1, 312) = 5.49, 
p = .01), but not opioid-
maintained individuals 
(β = -.007, F(1, 336) = 
0.00, p = .99; Figure 3-
3). In addition, there 
was a significant 




disadvantaged women of childbearing age, (F(5, 276) = 3.03, p = .01), where Intensity 
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was only significantly predictive of choice in the 0.4 v. 2.4, 5.2 v. 15.8 and 2.4 v 15.8 
dose comparisons. 
3.4.1. Elasticity.  Elasticity was significantly predictive of choice, β = -.22, F(1, 
880) = 14.25, p < .001.  Specifically, lower Elasticity difference scores were associated 
with greater preference for the higher dose cigarettes; for every 0.1 point decrease in 
Elasticity, preference for the higher dose cigarette increased by 2%.    
The final model used to assess the predictive utility of Elasticity differed by 
vulnerable population and dose comparison, Elasticity X Vulnerable Population X Dose 
Comparison:  F(2, 998) = 10.06, p < .001.  In all three vulnerable populations of interest, 
Elasticity was significantly, negatively associated with choice (Figure 3-4).  However, 
among opioid-maintained individuals, Elasticity was differentially predictive of choice 
across different dose comparisons (Elasticity X Dose Comparison: F(5, 298) = 3.96, p = 
.002), with Elasticity positively predictive of choice for the 2.4 v. 5.2 dose comparison 
and negatively predictive for all other dose comparisons.  
3.4.3. CPT Indices as Independent Predictors. When all five indices were 
included in a model to test which were independent predictors of cigarette preference, 
only Elasticity remained significant, β = -.21, F(1, 880) = 14.25, p < .001.  Lower 
Elasticity scores for the high dose cigarette corresponded to a higher proportion of 
choices for the high dose cigarette.  
3.5. Best Predictor of Choice 
 When all five mCEQ subscales and five CPT indices were included as predictor 
variables in a final model, Satisfaction and Enjoyment of Respiratory Tract Sensations 
were the only ones which remained predictive of choice preference for the higher dose 
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Figure 3-4.  Elasticity difference scores and cigarette choice preference across six 
dose comparisons (gray lines) and collapsed across dose comparisons (black lines) 
broken down by vulnerable population group. Among opioid-maintained individuals, 




CHAPTER 4: DISCUSSION 
In recent years, the FDA has taken steps to reduce the addictiveness of 
combustible products.  Relative reinforcing efficacy is a robust predictor of the addictive 
properties of nicotine containing products.  The present study tested the extent to which 
the mCEQ and CPT, two self-report measures, captured acute relative reinforcing effects 
of cigarettes which vary in nicotine content as measured by a behavioral measure, 
concurrent choice SA.   
4.1. mCEQ Predicting Choice 
Even though not all mCEQ subscales were predictive of SA when tested in the 
pilot sample, it is not surprising that all mCEQ subscales are significantly associated with 
choice, as mCEQ subscales query moods and sensations that typically accompany 
increases in nicotine dose (Benowitz et al., 2006; Boren et al., 1990; Butschky et al., 
1995; Gross et al., 1997; Hatsukami et al., 2013b; Higgins et al., 2017a; 2017b; Perkins et 
al., 1996; 2016; Shahan et al., 1999).  However, among all mCEQ subscales, Satisfaction 
and Enjoyment of Respiratory Tract Sensations subscales were the only independent 
predictors of choice.  In addition, while Satisfaction was a significant predictor across 
dose, the magnitude of prediction varied by population and was significantly greater 
among women of childbearing age who are socioeconomically disadvantaged. Follow-up 
analyses determined that statistically controlling for sex, age and education did not 
eliminate the strength of Satisfaction in predicting choice among these populations.  This 
suggests that sex, age and education, which were constrained among socioeconomically 
disadvantaged women of childbearing age due to specific inclusion criteria, did not drive 
the strength of the relationship between Satisfaction and choice.  While the predictive 
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utility appears to vary in strength among certain groups, the overall pattern is consistent: 
the greater a Satisfaction score is for a cigarette, the more likely it will be chosen.  These 
results paired with previous findings suggests that Satisfaction is the best subjective 
effect for predicting relative reinforcing efficacy measured in a concurrent choice 
paradigm (Arger et al., 2017; Perkins et al., 2018).  Building on Arger et al. (2017), our 
results also showed that the relationship between Satisfaction and choice was 
significantly positively related at every dose comparison, including between reduced 
nicotine content cigarettes.   
 The observation that Enjoyment of Respiratory Tract Sensations was an 
independent predictor of choice was somewhat inconsistent with the results of Arger et al 
(2017).  Although the direction of the relationship was similar in both set of analyses, it 
did not reach significance in Arger et al., perhaps due to issues around power and sample 
size.  Similar to Satisfaction, this subscale asks about the presence or absence of a 
positively reinforcing subjective effect but unlike Satisfaction, this subscale is a cigarette-
specific subjective effect.  Participants sampled these cigarettes under acute abstinence, 
which has been associated with increases in coughing and throat irritation, and laboratory 
research demonstrates that nicotine suppresses coughing following extended abstinence 
(Davenport, Vovk, Duke, Bolser & Robertson, 2009).  Given that both sampling and 
concurrent choice sessions were conducted under acute abstinence, it is possible that 
coughing and respiratory discomfort was heightened prior to the session and that 
cigarettes with higher nicotine doses better suppressed coughing and throat irritation and 
thereby provided more favorable sensations and therefore were more preferable.   
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 According to our results, the subjective effects that best predict relative 
reinforcing effects captured in concurrent choice SA paradigms are positive effects. This 
finding is consistent with both previous studies which have tested this relationship (Arger 
et al., 2017; Perkins et al., 2018).  One the other hand, negative reinforcing effects, more 
likely to be picked by items on the Craving Reduction and Psychological Reward 
subscales, were no longer predictive of choice when positive reinforcing effects were 
included in the model.  Somewhat unexpectedly, Aversion was not independently 
predictive of concurrent choice SA.  Follow-up analyses determined that the two items 
within the Aversion subscale (Nausea and Dizziness) predicted choice in opposite 
directions, with Nausea negatively associated with preference for the higher dose and 
Dizziness positively associated with preference for the higher dose.  This discrepancy is 
consistent with results from a confirmatory factor analysis of the mCEQ which found that 
Aversion had less internal consistency than the other mCEQ subscales for capturing 
subjective effects of reinforcement (Cappelleri et al., 2007). Our discrepant findings on 
Aversion and choice may speak to the lack of consistency of the subscale.  With regards 
to cigarettes varying in nicotine content, it appears that these two factors (Nausea and 
Aversion) should be considered separately as they function differently in terms of how 
they relate to actual drug taking in concurrent choice SA paradigms. 
4.2. CPT Predicting Choice 
 The utility of the CPT indices for predicting choice varied greatly across 
individual indices, vulnerable populations and dose comparisons.  Intensity and 
Elasticity, when tested separately, significantly predicted choice.  While the predictive 
utility of Intensity and Elasticity depended on which dose comparisons were being 
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analyzed within each vulnerable population, Elasticity was the most consistent predictor 
of choice across populations.  Among all three populations, the less sensitive to price 
(inelastic), the more often a dose was chosen.  This suggests that doses which are 
relatively less sensitive to environmental constraints are more likely to be preferred in a 
concurrent choice paradigm when two doses are available at equal response costs.  It is 
possible that the other CPT indices, Pmax, Breakpoint and Omax, which were not significant 
predictors of choice, do not isolate the reinforcing effects of a drug and instead capture 
individual differences related to the greatest costs an individual is willing to incur (e.g., 
Murphy et al., 2012, Dahne et al., 2017, O’Connor et al., 2014).  These features may be 
more relevant to an individual’s cigarette use history and less relevant to the acute 
reinforcing effects of a drug.  This question has not been tested directly but certainly 
warrants additional scientific attention.   
As already noted, the relationships between Elasticity, Intensity and choice varied 
depending on dose comparison and/or vulnerable population.  Among opioid-maintained 
individuals, dose comparisons which had the smallest dose discrepancies (e.g., 0.4 vs. 2.4 
and 2.4 vs. 5.2), showed less consistent predictive utility of Elasticity for choice. 
Furthermore, Intensity, while predictive of choice among socioeconomically 
disadvantaged women of childbearing age and individuals with affective disorders, was 
not predictive of choice among opioid-maintained individuals.  These population 
differences may be a function of the sensitivity of the CPT for detecting individual 
differences, which is not as frequently observed in mCEQ or choice preference (e.g., 
Higgins et al., 2018, Cappelleri et al., 2007).  For example, our group recently showed 
that among vulnerable population smokers, the Heaviness of Smoking Index (a measure 
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of cigarette dependence) corresponds to differences in CPT indices but not mCEQ 
subscales or concurrent choice preference across a range of doses (Figure 4-1).  
Specifically, smokers with higher dependence severity had greater Intensity (Q0) and 
Maximum Expenditure (Omax).   One component of the HSI is cigarettes smoked per day; 
given that Q0 and Omax correspond to this measure of dependence, it perhaps is not 
surprising that these two indices differentiated among different levels of dependence. In 
addition, as outlined in the Introduction, the CPT is predictive of many measures of the 
natural history of smoking (cigarettes per day, nicotine dependence, quit attempts, 
clinical outcomes).  Therefore, 
beyond assessing acute effects of 
cigarettes which vary in nicotine 
and predicting choice, the CPT also 
characterizes individuals with 
varying patterns of cigarette use.  
So far, it is unclear how 
different indices may correspond to 
unique aspects of addiction.  There 
is evidence that all five indices can 
serve as predictors of cigarettes smoked per day, nicotine dependence and 
psychopathology (Dahne et al. 2017, Murphy et al., 2012; Secades Villa et al., 2016, 
2017).  Our data, however, isolates Elasticity as a good measure for detecting acute 
relative reinforcing effects regardless of population, which distinguishes the utility of this 
index from the other four.  
Figure 4-1 Demand curves derived from the CPT by 
Heaviness of Smoking Index (HSI) scores. Adapted 
from “Higgins, S. T., Bergeria, C. L., Davis, D. R., 
Streck, J. M., Villanti, A. C. … Miller, M. E. (2018) 
Response to reduced nicotine content cigarettes 
among smokers differing in tobacco dependence 
severity. Preventive Medicine, In press.  
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4.3. Evaluating the Best Self-Report Predictor of Choice 
Satisfaction and Enjoyment of Respiratory Tract Sensations, but not Elasticity, 
remained predictive of concurrent choice SA.  This suggests that the mCEQ subscales are 
best at capturing acute relative reinforcing effects of cigarettes concurrently available at 
equal response costs.  The CPT incorporates how intensity of demand and sensitivity to 
environmental constraints influence the reinforcing properties of cigarettes which vary in 
nicotine content.  While Elasticity was predictive of concurrent choice SA when tested 
individually, mCEQ subscales more accurately captured the component of abuse liability 
measured in concurrent testing.  That said, increasing evidence suggests that the CPT is 
best for capturing unique features of abuse liability related to cigarette smoking in 
naturalistic settings where environmental constraints are ever present and smoking rates 
vary across subpopulations. 
4.4. Limitations and Future Directions.   
While our analyses provide a more rigorous evaluation of the mCEQ subscales and 
CPT indices for evaluating the acute reinforcing effects of smoking, our results should be 
considered in light of some limitations.   
First, while concurrent choice SA is a laboratory proxy for drug taking, a more 
thorough validation of the mCEQ and CPT would be to analyze how these measures 
correspond to rates of use outside of the laboratory. Therefore, the clinical utility of 
Satisfaction, Enjoyment of Respiratory Tract Sensations and Elasticity should be 
interpreted with caution until there is broader validation. 
Second, it is unclear how well the relationships between these mCEQ and CPT and 
SA data extend to other tobacco products.  According to a study by Stein and colleagues 
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(2017), the relationship between CPT indices and SA functioned differently depending on 
the tobacco product being assessed and perhaps how familiar the participant is with a 
product (cigarettes v. snus or nicotine gum). On the other hand, other studies have found 
evidence of consistencies across tobacco products when evaluating the relationship 
between subjective effects and SA (Arger et al., 2017; Hatsukami et al., 2013c; Perkins et 
al., 1996; 1997; 2018). 
Together, these limitations provide clear future directions for assessing how 
subjective effects and purchase tasks may be related to behavioral assessments of abuse 
liability. 
4.5. Conclusions 
 This study compared widely used measures for abuse liability and how well they 
assess relative reinforcing efficacy assessed in a concurrent choice SA paradigm.  All 
three measures provide unique insights into how cigarettes with varying levels of nicotine 
may maintain smoking behavior. Concurrent choice testing quantifies the acute relative 
reinforcing effects observed with direct drug taking, mCEQ subscales characterize the 
positive and negative reinforcing features of cigarette smoking, and the CPT shows how 
intensity of demand and environmental constraints influence the abuse liability of 
cigarettes which vary in nicotine content.  Together these data provide clarity with regard 
to the individual components of the mCEQ and CPT that best describe abuse liability in 
cigarettes which vary in nicotine content.  Furthermore, these methods (behavioral and 
self-report) capture unique facets of the abuse liability of cigarettes which vary in 
nicotine content.  When all three measures are used together, researchers will be better 
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able to comprehensively describe the abuse potential of cigarettes with varying levels of 
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